Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sherko Kuemmel

Showing results (41-50 of 81) with videos related to

Pageof 9
Sort By:
NPJ Breast Cancer|June 19, 2020
Evidence-based guidelines for managing patients with primary ER+ HER2- breast cancer deferred from surgery due to the COVID-19 pandemicMitch Dowsett, Matthew J Ellis, J Michael Dixon, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 2, 2016
West German Study Group Phase III PlanB Trial: First Prospective Outcome Data for the 21-Gene Recurrence Score Assay and Concordance of Prognostic Markers by Central and Local Pathology AssessmentOleg Gluz, Ulrike A Nitz, Matthias Christgen, et al.
Journal for Immunotherapy of Cancer|May 8, 2021
Immune cell composition and functional marker dynamics from multiplexed immunohistochemistry to predict response to neoadjuvant chemotherapy in the WSG-ADAPT-TN trialMonika Graeser, Friedrich Feuerhake, Oleg Gluz, et al.
The Lancet. Oncology|April 11, 2022
De-escalated neoadjuvant pertuzumab plus trastuzumab therapy with or without weekly paclitaxel in HER2-positive, hormone receptor-negative, early breast cancer (WSG-ADAPT-HER2+/HR-): survival outcomes from a multicentre, open-label, randomised, phase 2 trialUlrike Nitz, Oleg Gluz, Monika Graeser, et al.
JAMA Oncology|May 11, 2023
Efficacy of Endocrine Therapy Plus Trastuzumab and Pertuzumab vs De-escalated Chemotherapy in Patients with Hormone Receptor-Positive/ERBB2-Positive Early Breast Cancer: The Neoadjuvant WSG-TP-II Randomized Clinical TrialOleg Gluz, Ulrike A Nitz, Matthias Christgen, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 3, 2025
Multiomic Factor Analysis for Pathologic Complete Response after Pembrolizumab + Trastuzumab + Pertuzumab in HER2-Enriched Early Breast Cancer: WSG-Keyriched-1 TrialMonika Graeser, Oleg Gluz, Peter Schmid, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 3, 2019
Prospective, Multicenter, Randomized Phase III Trial Evaluating the Impact of Lymphoscintigraphy as Part of Sentinel Node Biopsy in Early Breast Cancer: SenSzi (GBG80) TrialSherko Kuemmel, Johannes Holtschmidt, Bernd Gerber, et al.
Cancer Medicine|November 15, 2021
TP53 mutations are associated with primary endocrine resistance in luminal early breast cancerIsabel Grote, Stephan Bartels, Leonie Kandt, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 8, 2023
Paclitaxel plus Eftilagimod Alpha, a Soluble LAG-3 Protein, in Metastatic, HR+ Breast Cancer: Results from AIPAC, a Randomized, Placebo Controlled Phase IIb TrialHans Wildiers, Anne Armstrong, Eveline Cuypere, et al.
Molecular Cancer|March 27, 2025
Immunomodulatory gene networks predict treatment response and survival to de-escalated, anthracycline-free neoadjuvant chemotherapy in triple-negative breast cancer in the WSG-ADAPT-TN trialDarren Korbie, Clare Stirzaker, Oleg Gluz, et al.
Pageof 9

Showing results (41-50 of 81) with videos related to

Sort By:
Pageof 9
NPJ Breast Cancer|June 19, 2020
Evidence-based guidelines for managing patients with primary ER+ HER2- breast cancer deferred from surgery due to the COVID-19 pandemicMitch Dowsett, Matthew J Ellis, J Michael Dixon, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 2, 2016
West German Study Group Phase III PlanB Trial: First Prospective Outcome Data for the 21-Gene Recurrence Score Assay and Concordance of Prognostic Markers by Central and Local Pathology AssessmentOleg Gluz, Ulrike A Nitz, Matthias Christgen, et al.
Journal for Immunotherapy of Cancer|May 8, 2021
Immune cell composition and functional marker dynamics from multiplexed immunohistochemistry to predict response to neoadjuvant chemotherapy in the WSG-ADAPT-TN trialMonika Graeser, Friedrich Feuerhake, Oleg Gluz, et al.
The Lancet. Oncology|April 11, 2022
De-escalated neoadjuvant pertuzumab plus trastuzumab therapy with or without weekly paclitaxel in HER2-positive, hormone receptor-negative, early breast cancer (WSG-ADAPT-HER2+/HR-): survival outcomes from a multicentre, open-label, randomised, phase 2 trialUlrike Nitz, Oleg Gluz, Monika Graeser, et al.
JAMA Oncology|May 11, 2023
Efficacy of Endocrine Therapy Plus Trastuzumab and Pertuzumab vs De-escalated Chemotherapy in Patients with Hormone Receptor-Positive/ERBB2-Positive Early Breast Cancer: The Neoadjuvant WSG-TP-II Randomized Clinical TrialOleg Gluz, Ulrike A Nitz, Matthias Christgen, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 3, 2025
Multiomic Factor Analysis for Pathologic Complete Response after Pembrolizumab + Trastuzumab + Pertuzumab in HER2-Enriched Early Breast Cancer: WSG-Keyriched-1 TrialMonika Graeser, Oleg Gluz, Peter Schmid, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 3, 2019
Prospective, Multicenter, Randomized Phase III Trial Evaluating the Impact of Lymphoscintigraphy as Part of Sentinel Node Biopsy in Early Breast Cancer: SenSzi (GBG80) TrialSherko Kuemmel, Johannes Holtschmidt, Bernd Gerber, et al.
Cancer Medicine|November 15, 2021
TP53 mutations are associated with primary endocrine resistance in luminal early breast cancerIsabel Grote, Stephan Bartels, Leonie Kandt, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 8, 2023
Paclitaxel plus Eftilagimod Alpha, a Soluble LAG-3 Protein, in Metastatic, HR+ Breast Cancer: Results from AIPAC, a Randomized, Placebo Controlled Phase IIb TrialHans Wildiers, Anne Armstrong, Eveline Cuypere, et al.
Molecular Cancer|March 27, 2025
Immunomodulatory gene networks predict treatment response and survival to de-escalated, anthracycline-free neoadjuvant chemotherapy in triple-negative breast cancer in the WSG-ADAPT-TN trialDarren Korbie, Clare Stirzaker, Oleg Gluz, et al.
Pageof 9